| Request a sample from "The Infoshop", another service of Global Information.
|
SUMMARY
Introduction
The enormous economic and social burden of cancer continues to grow in the
aging societies of Europe and Japan. National health care systems have the
unenviable task of determining how best to stretch finite resources to cover
cancer treatments. With manufacturers' pipelines packed with new and
potentially expensive cancer therapies, controlling drug costs will
undoubtedly be a high priority for national governments
Questions Answered in This Spectrum Report
The implementation of prospective payment systems is a key element in many
governments' health care cost-containment strategies, and accommodating new
oncology drugs in these systems will be a challenging task. What dilemma
does the expansion of these initiatives present for drug manufacturers?
Governments in Europe and Japan have acknowledged a valuable role for
appropriate offlabel use of cancer therapies, but tough reimbursement
restrictions severely limit physicians' prescribing freedoms. What are some
recent changes in reimbursement policies for offlabel prescribing? How do
these policies impact treatment guidelines, therapeutic decision making, and
drug pricing? A growing range of health care professionals are involved in
the treatment of cancer patients The promotion of integrated cancer care will
encourage closer collaboration between primary and secondary care sectors.
What types of disease management programs to coordinate cancer care are
being developed in some countries? How will these programs affect the
reimbursement of cancer therapies?
Scope
Current reimbursement environment for cancer therapies: focusing on the fi ve
largest European markets (France, Germany, Italy, Spain, and the United
Kingdom) and Japan Outlook and implications for the pharmaceutical industry:
how reimbursement policies in these markets affect drug manufacturers
Mentioned in This Spectrum Report
Companies
- Aguettant
- Amgen
- Arimidex
- AstraZeneca
- Axcan Pharma International
- Baxter
- Biolitec Pharma
- Boehringer Ingelheim
- Bristol-Myers Squibb
- Cell Therapeutics
- Centocor
- Chiron
- Cis Bio International
- Debioclinic
- Elan Pharma
- Fujisawa
- Genzyme
- Gilead Sciences
- GlaxoSmithkline
- Guilford Pharmaceuticals
- HRA Pharma
- Ilex Pharmaceuticals
- ImClone Systems
- Isotec
- Janssen-Cilag
- Ligand Pharmaceuticals
- Lilly France
- Medimmune Oncology
- Merck Lipha Santé
- Merck Santé
- Mundipharma
- Norton Healthcare
- Novartis Europharm
- OTL Pharma
- Pharmacia (Pfi zer)
- Pierre Fabre
- Roche
- Sanofi Synthélabo
- Sanofi -Aventis
- Schering AG
- Schering-Plough
- Servier
- Skyepharma
- Wyeth-Lederle
TABLE OF CONTENTS
- Executive Summary
- Strategic Considerations
- Stakeholder Implications
- Introduction
- France
- Pharmaceutical Pricing and Reimbursement
- Prospective Payment
- Pharmacy Decision Making
- Hospital Prescribing to Outpatients
- Cost Sharing
- Off-Label Prescribing
- National Cancer Plan
- Germany
- Pharmaceutical Pricing and Reimbursement
- Prospective Payment
- Integrated Care
- Disease Management
- Prescribing Budgets
- Cost Sharing
- Off-Label Prescribing
- Italy
- Pharmaceutical Pricing and Reimbursement
- Prospective Payment
- Exceptional Reimbursement
- Pharmacy Decision Making
- Off-Label Prescribing
- Financial Constraints
- Spain
- Pharmaceutical Pricing and Reimbursement
- Pharmacy Decision Making
- Access to Innovative Therapies
- United Kingdom
- Pharmaceutical Pricing and Reimbursement
- Prospective Payment
- Pharmacy Decision Making
- National Institute for Clinical Excellence
- Review of Variations in the Use of NICE-Approved Cancer Drugs
- Government Agency Criticizes Inadequate Implementation of NICE Guidance
- Patient Action Against Lack of Access to Certain Drugs
- Accelerated NICE Appraisal Process
- Off-Label Prescribing
- Japan
- Pharmaceutical Pricing and Reimbursement
- Prospective Payment
- Unavailability of Gold-Standard Therapies
- Off-Label Prescribing
- Outlook and Implications for the Pharmaceutical Industry
|
